Table 1.
BsAbs against cancers in clinical development
| Molecule | Targets | Format | MOAa | Indication | Statusb | Developed by |
|---|---|---|---|---|---|---|
| Catumaxomab | CD3 + EpCAM | TrioMab | T cell recruitment | Malignant ascites Gastric cancer Ovary cancer Epithelial cancer |
Market 2 2 1-2 |
Fresenius Biotech |
| FBTA05 | CD3 + CD20 | TrioMab | T cell recruitment | BCL | 1-2 | Fresenius Biotech |
| Ertumaxomab | CD3 + Her2 | TrioMab | T cell recruitment | Metastatic breast cancer | 2 | Fresenius Biotech |
| Blinatumomab (MT103) |
CD3 + CD19 | BiTE | T cell recruitment | B-ALL Relapsed/refractory ALL Pediatric ALL Relapsed NHL |
Market 2 1–2 1 |
Amgen |
| MT110 | CD3 + EpCAM | BiTE | T cell recruitment | Colorectal cancer Lung and gastrointestinal cancer |
1 1 |
Amgen |
| MT111 | CD3 + CEA | BiTE | T cell recruitment | Gastric cancer advanced adenocarcinoma | 1b | Amgen |
| AMG330 | CD3 + CD33 | BiTE | T cell recruitment | Relapsed/refractory AML | 1 | Amgen |
| MT112 | CD3 + PSMA | BiTE | T cell recruitment | Prostate cancer | 1 | Bayer |
| RG7221 | Angiopoietin 2 + VEGF | CrossMab | Two-ligand inactivation | Colorectal cancer | 2 | Roche |
| RG7597 | Her1 + Her3 | DAF-IgG | Two-RTK inactivation | Head and neck cancer, colorectal cancer | 2 | Genentech |
| MM111 | Her2 + Her3 | scFv-HSA | Two-RTK inactivation | Advanced gastric and esophageal cancer | 2 | Merrimack |
| MM141 | IGF1R + Her3 | scFv-IgG | Two-RTK inactivation | Advanced solid tumors | 1 | Merrimack |
| MGD006 | CD3 + CD123 | DART | T cell recruitment | AML | 1 | Macrogenics and Servier |
| MGD007 | CD3 + GPA33 | DART-Fc | T cell recruitment | Colorectal cancer | 1 | Macrogenics and Servier |
| AFM11 | CD3 + CD19 | TandAb | T cell recruitment | Non-Hodgkin’s lymphoma | 1 | Affimed |
| AFM13 | CD30 + CD16 | TandAb | NK cell recruitment | Hodgkin’s disease | 1 | Affimed |
| LY3164530 | Her1 + cMET | orthoFab-IgG | Two-RTK inactivation | Solid tumors | 1 | Eli Lilly |
| TF2 | CEA + hapten | D&L Fab3 | Payload delivery | Colorectal cancer | 1 | Immunomedics |
Information from ClinicalTrials.gov (http://clinicaltrials.gov)
aMOA, mode of action
b1, phase 1 clinical trials; 2, phase 2 clinical trials